Serum Biomarker That Reflects Use, Dose of Metformin Identified

Share this content:
Serum Biomarker That Reflects Use, Dose of Metformin Identified
Serum Biomarker That Reflects Use, Dose of Metformin Identified

WEDNESDAY, Dec. 21, 2016 (HealthDay News) -- The growth differentiation factor 15 (GDF15) is a novel biomarker for the use and dosing of metformin, according to a study published online Dec. 14 in Diabetes Care.

Hertzel C. Gerstein, M.D., from McMaster University in Hamilton, Canada, and colleagues assessed 237 serum biomarkers from participants in the Outcome Reduction with Initial Glargine Intervention trial to identify markers associated with metformin dosing or use. Of the 8,401 study participants, 2,317 were taking metformin.

The researchers found that GDF15 was strongly linked to metformin. For every one standard deviation increase in GDF15 level, the odds of metformin use varied from 3.73 to 3.94, depending on other variables included in the analysis. The odds ranged from 0.71 to 1.24 for the remaining 25 linked biomarkers. A 1.64 ng/mL higher GDF15 level predicted a 188-mg higher metformin dose (P < 0.0001).

"GDF15 levels are a biomarker for the use of metformin in people with dysglycemia, and its concentration reflects the dose of metformin," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Sanofi, which funded the study.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA Warns of Possible Heart Risks Linked to Clarithromycin

FDA Warns of Possible Heart Risks Linked to ...

Agency advising doctors to consider prescribing other antibiotics to patients with coronary heart disease

Artificial Intelligence May Help Prevent Physician Burnout

Artificial Intelligence May Help Prevent Physician Burnout

Many potential uses for AI, including improving searches and documentation, selecting treatment

Benzodiazepine Use Declining in Older Adults

Benzodiazepine Use Declining in Older Adults

Findings based on assessment of incidence, prevalence of use in three countries from 2010-2016

is free, fast, and customized just for you!

Already a member?

Sign In Now »